RxDoctor Payments Data

Donald Gutman, MD

Internal Medicine · Folsom, CANPI 1396776738

Payments from drug & device makers

$6,438in general payments, 2019–2025

Across 365 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$969
  • GSK$611
  • AstraZeneca$564
  • Boehringer Ingelheim$520
  • Novo Nordisk$514
  • Pfizer$509
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,438 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$161,201
Medicare patients
495
Services billed
1,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban402$194,387
JardianceEmpagliflozin142$164,327
OzempicSemaglutide85$90,407
MyrbetriqMirabegron100$70,530
XareltoRivaroxaban92$70,061
Wellbutrin XlBupropion Hcl11$62,314
JanuviaSitagliptin Phosphate39$30,715
MounjaroTirzepatide15$28,740
EntrestoSacubitril/Valsartan31$21,414
OxycontinOxycodone Hcl12$20,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,394
FarxigaDapagliflozin Propanediol11$16,067
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen629$15,002
Tresiba Flextouch U-100Insulin Degludec17$12,384
Soliqua 100-33Insulin Glargine/Lixisenatide13$11,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$509$200,801418 claims
Boehringer IngelheimJardiance, Tradjenta$520$173,699168 claims
Novo NordiskOzempic$514$90,40785 claims
Astellas Pharma US IncMyrbetriq$137$70,530100 claims
Johnson & JohnsonXarelto$286$70,06192 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$611$33,45866 claims
MerckJanuvia$155$30,71539 claims
Lilly USA, LLCMounjaro$109$28,74015 claims
AstraZenecaFarxiga, Lokelma$564$26,05322 claims
NovartisEntresto$35$21,41431 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$38$11,52413 claims
Sumitomo Pharma America, Inc.Gemtesa$97$5,68112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →